The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | Pre-MEASURE: patients with AML in complete remission but high risk of relapse following alloHCT
Measurable residual disease (MRD) prior to allogeneic hematopoietic cell transplantation (alloHCT) is associated with an increased risk of relapse and death in patients with acute myeloid leukemia (AML). In this interview, Christopher Hourigan, MD, DPhil, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, presents the results of Pre-MEASURE, a multicenter evaluation of the prognostic significance of MRD testing prior to allogeneic transplantation for adult patients with AML in first remission. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
